Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
10.12.2021 09:15:00 EET | Business Wire | Press release
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma Executive Committee as of 17 January 2022.
Hervé Gisserot, a French citizen, is an experienced industry executive and has a proven track record of building and leading organizations across the U.S., Europe and Asia Pacific with extensive launch and market access experiences. He joins from GlaxoSmithKline where he served in multiple Senior Vice President roles in the last 13 years. He is a graduate of the Institute of Political Science Paris (IEP), and has completed the General Management program at INSEAD.
With this new appointment, the President US, the Regional Commercial Heads, the Rare Disease BU, the central commercial, marketing and pricing teams, will report to the Chief Commercial Officer. This is to lead the organization ahead of expected approvals and subsequent launches of four pipeline products in the next 18 months, and to maximize opportunities of our iron portfolio.
Abbas Hussain, Chief Executive Officer of Vifor Pharma Group, commented: “I am delighted that Hervé joins Vifor Pharma. He brings a wealth of commercial experience from leading pharmaceutical companies at an international level, delivering profitable growth across multiple therapeutic areas and markets. His professional background makes him ideally suited to lead the commercial organization and to put a strong focus on execution as we accelerate growth to become a multi-brand organization focused on in-licensing, partnering and commercializing products worldwide.”
Photo:
A picture of Hervé Gisserot is available for download at viforpharma.com/media/media-library
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005908/en/
Contact information
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio ® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label extension study in adults and adolescents with moderate-to-severe atopic dermatitis’, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, on Thursday, October 1, from 10:45-10:55 AM CET in Hall N by Dr. Matthias Augustin, an ARCADIA clinical trial investigator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929663019/en/ “These three-year data provide important evi
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill30.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s superior efficacy compared to deucravacitinib and reinforce the potential for zasocitinib to deliver rapid, durable and consistent skin clearance in a convenient once-daily pill.2-5 “Psoriasis is a heterogeneous disease driven by multiple immune pathways and TYK2 plays a central role in regulating several key inflammatory signals,” said Chinwe Ukomadu, M.D., Ph.D., Senior Vice President and Head, Gastrointestinal & Inflammation Therapeutic Area Unit at Takeda. “Across our Phase 3 trials, zasocitinib demonstrated superiority versus two distinct oral thera
Ant International’s Antom Supports Google Gemini in Expanding Access to AI Service in Asia30.9.2026 07:16:00 EEST | Press release
Google Gemini and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership to make AI tools for learning, creativity and productivity more accessible to users in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929520038/en/ Google AI Plus free trial offers are available in select digital payment and retail channels partnering with A+Rewards in Indonesia, with more markets to follow. Promoting Google AI Plus through AI-powered growth engine The collaboration will leverage A+Rewards, Antom’s digital marketing solution powered by privacy-preserving computing and AI technologies, and its extensive partner network of digital payment apps, e-commerce platforms and lifestyle service providers, to help expand access to Google AI Plus. Integrated into more than 30 leading digital platform partners, A+ Rewards provides in-app entry points where users
Signaloid Joins CERN openlab's Heterogeneous Architectures Testbed to Explore the Future of Scientific Computing30.9.2026 07:00:00 EEST | Press release
British computing company Signaloid has joined CERN openlab, the public-private partnership through which CERN evaluates emerging information technologies for scientific computing. As part of the collaboration, CERN and Signaloid will evaluate Signaloid's distribution-extended compute hardware (UxHw®) technology within the CERN openlab Heterogeneous Architectures Testbed, which explores new processor technologies for future scientific computing infrastructures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929985154/en/ Signaloid joins CERN openlab: Putting Signaloid's UxHw® Technology to the Test at the World's Largest Particle Collider The collaboration comes as research organisations worldwide are increasingly adopting heterogeneous computing architectures that combine CPUs, GPUs and specialised accelerators to tackle demanding workloads more efficiently. As the High-Luminosity Large Hadron Collider (HiLumi LHC) appro
FPT Named in Forrester’s The SAP Services Landscape Report30.9.2026 06:00:00 EEST | Press release
Global technology corporation FPT has been included among the notable providers in The SAP Services Landscape, Q3 2026, published by Forrester Research, Inc. The report provides an overview of SAP services providers, examining their market focus, geographic presence, and business specializations to support enterprises in evaluating potential technology partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929359531/en/ The report includes FPT as a systems integrator with an Asia Pacific geographic focus and an industry focus spanning financial services and insurance, healthcare, and manufacturing. FPT identified SAP Business Data Cloud, SAP Enterprise Resource Planning (ERP), and SAP Supply Chain Management (SCM) as its three primary extended business scenario focus areas, what FPT believes reflects its emphasis on modernizing core enterprise systems and enabling more integrated, data-driven operations. Building on mor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom